Oppenheimer Adjusts ACADIA Pharmaceuticals Price Target to $17 From $19, Maintains Perform Rating

ACADIA Pharmaceuticals (ACAD) has an average rating of outperform and price targets ranging from $13 to $39, according to analysts polled by Capital IQ. Price: 15.45, Change: +0.24, Percent Change: +1

MT NewswiresMay 10 22:01

Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA), Integer Holdings (ITGR) and ACADIA Pharmaceuticals (ACAD)

TipRanksMay 10 20:20

ACADIA Pharmaceuticals Is Maintained at Neutral by B of A Securities

ACADIA Pharmaceuticals Is Maintained at Neutral by B of A Securities

Dow JonesMay 10 19:59

ACADIA Pharmaceuticals First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Yahoo FinanceMay 10 19:58

B of A Securities: Maintaining the ACADIA Pharmaceuticals (ACAD.US) rating, adjusted from neutral to neutral, and adjusted the target price from $26.00 to $22.00.

B of A Securities: Maintaining the ACADIA Pharmaceuticals (ACAD.US) rating, adjusted from neutral to neutral, and adjusted the target price from $26.00 to $22.00.

Zhitong FinanceMay 10 19:51

B of A Securities Maintains Neutral on ACADIA Pharmaceuticals, Lowers Price Target to $22

B of A Securities analyst Tazeen Ahmad maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Neutral and lowers the price target from $26 to $22.

BenzingaMay 10 19:48